The novel B-cell epitope peptide vaccine, MAX449, exhibits significant anti-tumor efficacy and enhances the therapeutic effects of PD-1 antibodies on tumors by modulating the activity of PMN-MDSCs - P
10 hours ago
- #peptide vaccine
- #PD-1 antibody
- #cancer immunotherapy
- MAX449 is a novel B-cell epitope peptide vaccine with significant anti-tumor efficacy.
- The vaccine enhances the therapeutic effects of PD-1 antibodies by modulating PMN-MDSCs activity.
- MAX449 induces high titer C5a antibodies, blocking the C5a-C5aR pathway in PMN-MDSCs.
- It suppresses tumor growth by downregulating CCRL2 and reducing IL-1β production via the NF-κB pathway.
- The vaccine promotes expansion of anti-tumor CD8+ T cells and boosts PD-1 antibody efficacy in both cold and hot tumor models.
- Research supports clinical evaluation of MAX449 as an innovative cancer therapy.